结核病短程治疗研究:回顾与展望  

Short-course treatment for tuberculosis:past achievements and future directions

作　　者：李杨 孙峰[1,2] 张文宏 Li Yang;Sun Feng;Zhang Wenhong(National Medical Center for Infectious Diseases,Huashan Hospital,Fudan University,Shanghai 200040,China;Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response,Shanghai Sci-Tech Inno Center for Infection and Immunity,Shanghai 200040,China)

机构地区：[1]国家传染病医学中心/复旦大学附属华山医院,上海200040 [2]上海市传染病与生物安全应急响应重点实验室/上海市感染与免疫科技创新中心,上海200040

出　　处：《中国防痨杂志》2024年第9期991-997,共7页Chinese Journal of Antituberculosis

基　　金：上海申康医院发展中心临床三年行动计划资助(SHDC2020CR1011B);上海市加强公共卫生体系建设三年行动计划(2020—2022年)(GWV-3.1);国家自然科学基金青年基金(82102406);上海申康医院发展中心模拟RCT项目(SHDC2024CRI047);上海市科技重大专项(HS2021SHZX001)。

摘　　要：目前,结核病疫情下降速度缓慢,距离世界卫生组织“终止结核病策略”所设定的里程碑目标仍有较大差距,研发并应用有效的短程治疗方案变得至关重要。本文旨在回顾过去几十年中结核病短程治疗的发展历程,评估当前治疗方法的有效性,以期为未来结核病短程治疗策略的优化提供依据和参考。通过系统性回顾文献和最新的临床试验数据,笔者分析了多种短程治疗方案的疗效、安全性,以及应用场景;并分析、归纳目前短程治疗的主要策略。尽管存在挑战,但通过新型药物的开发、药物剂量优化和更精准的患者评估,结核病的短程治疗有望在未来几年内取得显著进展。The global decline in tuberculosis(TB)incidence has been disappointingly slow,significantly lagging behind the milestones set by the World Health Organization’s End TB Strategy.Consequently,the development and implementation of effective short-course treatment regimens have become imperative.This review aims to examine the progress of short-course TB treatments over the past few decades and evaluate the efficacy of current therapeutic approaches,providing essential references and support for optimizing future treatment strategies.Through a systematic review of the literature and the latest clinical trial data,we analyzed the efficacy,safety,and application scenarios of various short-course treatment regimens.Furthermore,we summarized the main strategies for current short-course treatments.Despite existing challenges,significant progress in tuberculosis short-course treatment is anticipated in the coming years,driven by the development of novel drugs,dose optimization,and more precise patient evaluation.

关 键 词：结核 临床方案 治疗应用 总结性报告(主题) 

分 类 号：R52[医药卫生—内科学] R825.2[医药卫生—临床医学]